Last updated: September 8, 2026
Ipatasertib is an oral, selective pan-AKT inhibitor that reached Phase 3 testing in prostate and breast cancer but did not establish a viable registration path. The most important development programs produced mixed or negative results, and no ipatasertib product has FDA approval, an Orange Book listing, marketed revenue, or approved-drug exclusivity. Commercial prospects are therefore limited unless a new biomarker-defined indication produces a clear late-stage benefit.
What is the current development status of ipatasertib?
Ipatasertib, also known as GDC-0068 and RG7440, is an investigational small-molecule inhibitor of AKT1, AKT2, and AKT3. Roche and Genentech developed the drug with AstraZeneca under a collaboration covering AKT inhibitors and selected oncology programs.
The development program concentrated on tumors driven by the PI3K/AKT/PTEN pathway, including:
- Metastatic castration-resistant prostate cancer
- Hormone receptor-positive, HER2-negative breast cancer
- Triple-negative breast cancer
- Other solid tumors with PTEN loss or PI3K/AKT pathway activation
The program advanced to Phase 3 but failed to produce a broad regulatory opportunity. Public clinical-trial records and Roche disclosures do not identify a currently active pivotal program supporting an imminent FDA filing. Ipatasertib remains investigational rather than commercially available.
Ipatasertib development timeline
| Year |
Development event |
| 2010-2011 |
AstraZeneca and Genentech/Roche advanced AKT-pathway inhibitor research, including ipatasertib |
| 2014 |
Early clinical studies reported activity in metastatic prostate and breast cancer |
| 2018 |
The Phase 3 IPATential150 prostate-cancer trial began reporting |
| 2020 |
IPATential150 met its radiographic progression-free survival endpoint in the overall population, but the clinical benefit was limited |
| 2021 |
The trial failed to show a statistically significant overall-survival benefit in the full analysis population |
| 2020-2022 |
IPATunity130 breast-cancer cohorts reported negative or non-supportive results |
| 2022-2024 |
No public evidence established a new registration-directed Phase 3 strategy |
| Current status |
Investigational asset with no FDA approval and no commercial launch |
Sources include ClinicalTrials.gov records and Roche annual-report disclosures.[1,2]
What clinical trials determine ipatasertib’s commercial outlook?
The strongest evidence came from the Phase 3 IPATential150 trial in metastatic castration-resistant prostate cancer.
IPATential150 prostate-cancer trial
IPATential150 evaluated ipatasertib plus abiraterone and prednisone versus placebo plus abiraterone and prednisone in men with previously untreated metastatic castration-resistant prostate cancer.
The trial enrolled approximately 1,100 patients and included a prespecified subgroup with PTEN-loss tumors. Its design reflected the commercial hypothesis that blocking AKT could overcome resistance to androgen-receptor pathway inhibition.
The results were mixed:
- The primary radiographic progression-free survival endpoint was met in the PTEN-loss population.
- The benefit was not sufficient to establish broad efficacy across the overall study population.
- Overall-survival results did not demonstrate a statistically significant benefit in the full analysis population.
- Safety was less favorable than abiraterone and prednisone alone, with increased diarrhea, rash, hyperglycemia, and treatment discontinuation.
The data supported biological activity in PTEN-loss disease but did not provide a clear basis for an unrestricted prostate-cancer label. Roche’s subsequent public disclosures did not indicate a successful regulatory filing for ipatasertib in this indication.[2,3]
IPATunity130 breast-cancer trials
The IPATunity130 program tested ipatasertib in combination with chemotherapy in advanced breast cancer.
The Phase 3 cohort evaluating first-line treatment for patients with metastatic triple-negative breast cancer and PIK3CA/AKT1/PTEN-altered tumors did not meet its primary progression-free-survival endpoint. The second cohort in hormone receptor-positive, HER2-negative disease also failed to demonstrate the required benefit.
The breast-cancer results weakened the case for a tumor-agnostic or pathway-selected commercial strategy. They also reduced the probability that ipatasertib could compete with approved or emerging targeted therapies in PI3K/AKT-pathway disease.[4]
Is ipatasertib FDA approved?
No. Ipatasertib does not have FDA approval for prostate cancer, breast cancer, or any other indication.
Because it is not approved:
- It has no FDA-approved label.
- It has no New Drug Application approval date.
- It has no FDA-granted five-year new chemical entity exclusivity.
- It has no three-year clinical-investigation exclusivity.
- It has no approved pediatric exclusivity.
- It has no U.S. commercial product revenue attributable to a marketed ipatasertib product.
The drug should not be treated as an approved alternative to alpelisib, capivasertib, abiraterone, enzalutamide, or other marketed oncology products.
What is the Orange Book status of ipatasertib?
Ipatasertib has no Orange Book listing because FDA has not approved an ipatasertib product.
The absence of an Orange Book listing means there is currently no listed U.S. patent set against which an ANDA applicant could submit a standard Paragraph IV certification. Any future generic challenge would depend on FDA approval of an originator product and subsequent listing of applicable patents.
This distinction matters for market timing. Ipatasertib has patent rights, but those rights do not create a current Hatch-Waxman blocking period because no approved product exists.
What patents protect ipatasertib?
Ipatasertib is covered by patent families directed to AKT-inhibitor chemical compounds, pharmaceutical compositions, treatment methods, and related use claims. AstraZeneca was a principal originator of the underlying chemistry, with Roche/Genentech involved in later development and commercialization arrangements.
Public patent records associate ipatasertib with international patent families covering substituted heterocyclic compounds and their use as AKT inhibitors. Representative early application families include WO2011048307 and related national filings, although the exact claims, ownership, terminal disclaimers, continuations, and enforceable expiration dates must be reviewed in each jurisdiction.[5]
Patent categories relevant to ipatasertib
| Patent category |
Commercial relevance |
Current status |
| Composition-of-matter claims |
Core protection for the ipatasertib molecule and chemical analogues |
Likely the strongest historical protection |
| Pharmaceutical-composition claims |
Covers drug-containing formulations and dosage forms |
Potentially relevant after composition claims expire |
| Method-of-treatment claims |
Covers treatment of cancers using ipatasertib |
Scope depends on tumor type, biomarker, dose, and claim language |
| Combination-treatment claims |
Covers ipatasertib with abiraterone, chemotherapy, or other agents |
Potentially relevant to combination regimens |
| Manufacturing claims |
Covers processes, intermediates, or solid forms |
May create manufacturing barriers but normally does not prevent all independent synthesis |
| Formulation claims |
Covers specific oral formulations or excipient systems |
No public evidence indicates a commercially important marketed formulation |
The principal legal limitation is that patent duration does not equal commercial exclusivity. A patent may remain in force while the asset has no approved product, no reimbursed indication, and no viable registration program.
When does ipatasertib lose patent exclusivity?
The effective U.S. and European expiration dates cannot be stated as a single date without separating the relevant patent families and confirming patent-term adjustments, patent-term extensions, continuations, and jurisdiction-specific status.
The early composition-of-matter families were filed around 2010-2011. On a simple 20-year term from the earliest nonprovisional priority or international filing structure, core rights would generally be expected to fall in the early 2030s, subject to applicable adjustments and national prosecution history.
Later method, combination, formulation, and manufacturing patents may expire after the core composition claims. Those later rights could affect a narrow approved use but would not necessarily block an independent generic or alternative indication.
For commercial analysis, the relevant sequence is:
- Core chemical patent term.
- Patent-term adjustment or extension.
- Later formulation and method-of-use claims.
- Regulatory exclusivity, if any.
- Actual approval and launch date.
Because ipatasertib has no approved product, the practical generic-entry date is currently undefined. A future approval could create a separate exclusivity timeline, but no such timeline is presently running.
Are there Paragraph IV challenges to ipatasertib patents?
No material public Paragraph IV litigation is associated with ipatasertib.
The reason is structural: Paragraph IV litigation generally follows submission of an ANDA referencing an approved drug with Orange Book-listed patents. Ipatasertib has no approved reference product and no Orange Book patent listing.
A future approval could produce:
- Paragraph III certifications to patents expiring before generic launch.
- Paragraph IV certifications challenging validity, enforceability, or infringement.
- Section viii statements carving out patented methods of use.
- Litigation under the Hatch-Waxman framework.
At present, there is no established generic launch sequence and no public ANDA-driven ipatasertib patent settlement.
What patent litigation affects ipatasertib?
No major public patent litigation has been identified as a current commercial constraint for ipatasertib.
The absence of litigation does not establish that every patent claim is valid or enforceable. It reflects the fact that no approved commercial product has created a conventional generic challenge. The key legal exposure remains future validity and freedom-to-operate analysis around:
- The core AKT-inhibitor structure.
- Salt, polymorph, and solid-state claims.
- Synthetic intermediates and manufacturing processes.
- Combination use with abiraterone or chemotherapy.
- PTEN-loss and other biomarker-defined treatment claims.
How strong is the ipatasertib patent estate?
The estate is technically credible but commercially underutilized.
Strengths
- Early composition patents may protect the active molecule through the early 2030s, subject to jurisdiction-specific adjustments.
- The drug has a defined mechanism and extensive clinical history.
- Combination and biomarker-based claims may create secondary protection.
- Manufacturing and formulation patents could increase development complexity for a future entrant.
Weaknesses
- No approved product currently creates market value for the patents.
- Clinical results did not establish a broad label.
- Method-of-use claims may be vulnerable to non-infringing treatment strategies.
- Later patents cannot restore the commercial value of a failed clinical program unless a new indication succeeds.
- The AKT inhibitor class has competing approved and investigational products.
Overall, the patent estate is stronger as a defensive asset than as a current revenue-generating asset.
What formulations are protected by ipatasertib patents?
Ipatasertib was developed as an oral small-molecule drug, generally administered in tablet form in clinical studies. Public development materials do not establish a commercially launched formulation with a distinct market identity.
Potential formulation protection may cover:
- Oral tablets.
- Specific crystalline or amorphous forms.
- Salt or solid-state forms.
- Excipients and manufacturing parameters.
- Dose regimens associated with intermittent or continuous administration.
No formulation patent has created a known commercial barrier comparable to the core composition patent. The most important formulation issue would arise only if Roche or a successor revived the program and obtained approval for a particular solid form or dosage technology.
Which companies are challenging ipatasertib?
No company has emerged as a publicly disclosed commercial challenger through an ipatasertib ANDA or biosimilar pathway.
Ipatasertib is a synthetic small molecule, so biosimilar competition is not applicable. Any future competition would come from generic small-molecule manufacturers or rival targeted oncology products.
Relevant competitive products and classes include:
| Product or class |
Company |
Strategic relevance |
| Capivasertib plus fulvestrant |
AstraZeneca |
Approved AKT-pathway competitor in HR-positive, HER2-negative advanced breast cancer |
| Alpelisib |
Novartis |
Approved PI3K-alpha inhibitor for PIK3CA-mutated breast cancer |
| Abiraterone |
Generic and branded suppliers |
Combination backbone evaluated with ipatasertib in prostate cancer |
| Enzalutamide and other androgen-receptor inhibitors |
Multiple companies |
Competing treatments in metastatic prostate cancer |
| Chemotherapy and antibody-drug conjugates |
Multiple companies |
Competing options in triple-negative breast cancer |
| Other AKT, PI3K, and mTOR inhibitors |
Multiple developers |
Compete for biomarker-selected pathway-driven tumors |
Capivasertib is the most direct commercial comparator because it validates AKT inhibition in breast cancer while narrowing the opportunity for an undifferentiated ipatasertib revival.[6]
How does ipatasertib compare with capivasertib?
Capivasertib has a materially stronger commercial position.
| Metric |
Ipatasertib |
Capivasertib |
| Regulatory status |
Investigational |
FDA-approved in combination with fulvestrant |
| Primary established market |
None |
HR-positive, HER2-negative advanced or metastatic breast cancer with pathway alterations |
| Phase 3 outcome |
Mixed or negative across major programs |
Positive registration-supporting data |
| Orange Book status |
None |
Applicable approved-product listings |
| Generic-entry framework |
Undefined |
Defined by approved product and listed patents |
| Commercial revenue |
None |
Commercially marketed |
| Strategic owner |
Roche/Genentech development history with AstraZeneca origins |
AstraZeneca |
| Biomarker strategy |
PTEN loss and PI3K/AKT alterations |
PIK3CA, AKT1, or PTEN alterations in approved setting |
Ipatasertib would need a differentiated efficacy, safety, dosing, or combination profile to displace capivasertib. Existing public data do not show that differentiation.
What is the market projection for ipatasertib?
The base-case market projection is zero current sales and low probability of near-term commercial launch.
Scenario-based market outlook
| Scenario |
Probability assessment |
Market implication |
| No further meaningful development |
Highest |
No product revenue; patents retain defensive or licensing value |
| Revival in a biomarker-selected prostate indication |
Low |
Niche oncology product, potentially below blockbuster scale |
| Revival in breast cancer |
Very low |
Significant competitive pressure from approved AKT and PI3K therapies |
| New combination or tumor-specific development |
Low |
Revenue depends on a new sponsor, biomarker signal, and successful Phase 3 trial |
| Out-licensing or asset sale |
Possible but uncertain |
Value would center on clinical data, patent life, and a credible development plan |
A reasonable commercial ceiling for a successful revival would be a targeted specialty-oncology product rather than a broad blockbuster. A PTEN-loss prostate-cancer label could address a meaningful population, but treatment would face competition from established androgen-receptor agents, taxanes, radioligand therapy, PARP inhibitors in selected patients, and other emerging therapies.
The product’s revenue potential is constrained by:
- Lack of approval.
- Prior Phase 3 setbacks.
- Combination-treatment toxicity.
- Need for biomarker testing.
- Competition from capivasertib.
- Long development time before any launch.
- Potentially short effective commercial life after regulatory approval.
No reliable consensus sales forecast supports a near-term ipatasertib revenue estimate. The defensible projection is zero current revenue, with only contingent future value tied to a successful clinical restart.
What generic launch risks exist for ipatasertib?
A future generic launch would face two different risk profiles.
Risk to a future originator
If ipatasertib were approved, the originator could face:
- Paragraph IV challenges to composition or method patents.
- Section viii carve-outs around patented biomarker or combination uses.
- Generic entry after core patent expiry.
- Competition from capivasertib and other targeted therapies before patent expiry.
- Reimbursement pressure in a crowded oncology market.
Risk to a future generic manufacturer
A generic company would face:
- Unclear commercial demand because there is no current reference product.
- Possible composition, polymorph, and process patents.
- Limited market size for a biomarker-defined indication.
- Difficulty designing around combination-treatment claims.
- Clinical and regulatory uncertainty if the originator label is narrow.
The primary barrier is not a current patent lawsuit. It is the absence of an approved market large enough to justify a generic filing.
What licensing deals involve ipatasertib?
Ipatasertib originated in the AstraZeneca-Geneva? No. The relevant development relationship was between AstraZeneca and Genentech/Roche, under which Roche obtained rights to develop and commercialize selected AKT inhibitors, including ipatasertib, in oncology.
Public disclosures identify Roche and Genentech as the principal development organizations for ipatasertib, while AstraZeneca was associated with the underlying research and collaboration framework.[2,7]
No major recent licensing transaction has restored ipatasertib to active late-stage development. The asset’s licensing value would depend on whether a new sponsor can identify a treatment population with a clinically meaningful benefit that was not demonstrated in the prior broad Phase 3 programs.
Key Takeaways
- Ipatasertib is an investigational oral pan-AKT inhibitor with no FDA approval.
- The IPATential150 prostate-cancer trial showed a PTEN-loss progression-free-survival signal but did not establish a broad overall-survival benefit.
- IPATunity130 breast-cancer trials did not support registration.
- There is no Orange Book listing, approved-drug exclusivity, marketed revenue, or established Paragraph IV litigation.
- Core patent families filed around 2010-2011 may extend into the early 2030s, subject to national patent records and term adjustments.
- The patent estate has defensive value but limited current commercial value.
- Capivasertib is the leading commercial comparator and has a stronger regulatory and market position.
- The base-case forecast is no near-term launch and zero current ipatasertib revenue.
- A future opportunity would require a new sponsor, a biomarker-defined indication, and convincing late-stage evidence.
FAQs About Ipatasertib
Is ipatasertib still being developed?
Public evidence does not show an active registration-directed program capable of supporting near-term approval. The major Phase 3 programs produced mixed or negative results.
Can ipatasertib be prescribed for prostate cancer?
No. Ipatasertib is not FDA approved and should not be treated as an approved prostate-cancer therapy.
Is ipatasertib a biosimilar risk?
No. Ipatasertib is a synthetic small molecule. Any future copy would be a generic drug, not a biosimilar.
Does ipatasertib compete with capivasertib?
Yes. Both are oral AKT inhibitors intended for pathway-driven cancers. Capivasertib has the stronger position because it has FDA approval and commercial validation.
Could ipatasertib be licensed to another oncology company?
Yes, but the commercial case would depend on new clinical differentiation. Existing Phase 3 results and the lack of approval reduce the asset’s standalone licensing value.
References
-
ClinicalTrials.gov. (n.d.). A study of ipatasertib plus abiraterone plus prednisone/prednisolone versus placebo plus abiraterone plus prednisone/prednisolone in participants with metastatic castration-resistant prostate cancer (IPATential150). U.S. National Library of Medicine.
-
Roche Holding AG. (2021-2024). Annual report and financial reporting disclosures. Basel, Switzerland: Roche.
-
de Bono, J. S., et al. (2020). Ipatasertib plus abiraterone and prednisone in metastatic castration-resistant prostate cancer: Results from the Phase 3 IPATential150 trial. The Lancet, 396, 131-142.
-
ClinicalTrials.gov. (n.d.). Studies of ipatasertib in combination with chemotherapy in patients with advanced breast cancer. U.S. National Library of Medicine.
-
World Intellectual Property Organization. (2011). WO2011048307: Heterocyclic compounds as AKT inhibitors. Geneva, Switzerland: WIPO.
-
U.S. Food and Drug Administration. (2023). FDA approves capivasertib with fulvestrant for breast cancer. Silver Spring, MD: FDA.
-
Genentech. (2011-2020). Ipatasertib clinical development and investor-relations materials. South San Francisco, CA: Genentech.